Fragment-based Approaches in Drug Discovery
Wolfgang Jahnke · Daniel A. Erlanson · Raimund Mannhold · Hugo Kubinyi · Gerd Folkers
dec. 2006 · John Wiley & Sons
Carte electronică
391
Pagini
reportEvaluările și recenziile nu sunt verificate Află mai multe
Despre această carte electronică
This first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and strategies in pharmaceutical ligand design. The book is clearly divided into three sections on ligand design, spectroscopic techniques, and screening and drug discovery, backed by numerous case studies.
Despre autor
Wolfgang Jahnke is a Senior Research Investigator at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. During his ten years at Novartis, he has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU Munchen, working with Horst Kessler on the development and application of novel NMR methods. He subsequently carried out research with Peter Wright at the Scripps Research Institute in La Jolla.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Evaluează cartea electronică
Spune-ne ce crezi.
Informații despre lectură
Smartphone-uri și tablete
Instalează aplicația Cărți Google Play pentru Android și iPad/iPhone. Se sincronizează automat cu contul tău și poți să citești online sau offline de oriunde te afli.
Laptopuri și computere
Poți să asculți cărțile audio achiziționate pe Google Play folosind browserul web al computerului.
Dispozitive eReader și alte dispozitive
Ca să citești pe dispozitive pentru citit cărți electronice, cum ar fi eReaderul Kobo, trebuie să descarci un fișier și să îl transferi pe dispozitiv. Urmează instrucțiunile detaliate din Centrul de ajutor pentru a transfera fișiere pe dispozitivele eReader compatibile.
